PharmEng inks Chinese joint venture deal

This was a recent article on DrugResearcher.com, by Emilie Reymond. The article goes into detail about the recent merger between two pharmaceutical companies.

Canada's PharmEng and Chinese firm Beijing BRD Lixin PharmaTech have signed a joint venture to provide consulting and pharma development services in China.

The deal announced this week will combine the two companies' areas of expertise. PharmEng will provide Lixin with consulting services in US cGMP standards, European GMP and other areas of North American regulatory and compliance requirements, while Lixin, with its client base, will provide PharmEng's contract manufacturing division Keata Pharma with a resource base of manufacturers and distributors for the supply of active pharmaceutical ingredients (APIs).

PharmaEng is confident that Lixin will provide the firm with a solid base for the expansion of consulting opportunities in China - Lixin specialises in consulting services in good manufacturing practices (GMP), validation and engineering design to Chinese manufacturers.

China has recently been dubbed as the favourite destination for outsourcing stages of the drug development and there is a growing amount of preclinical and clinical studies that are being conducted in the country - especially due to the low costs involved.

As a result, efforts are increasingly being made to harmonise manufacturing processes across China and North America. An important aspect is achieving valid data using processes that are acceptable to global regulatory standards.

"PharmEng will become a channel for two-way pharmaceutical consulting and trade between North America and China for access to cost effective APIs, formulations and technology transfers for off-patent drugs, consulting services and exclusive agency and distribution agreements in North America," the company said.

Under the terms of the deal, PharmEng will own 51 per cent of the joint venture company, headquartered in Beijing and will operate under the name Beijing PharmEng BRD Lixin PharmaTech Consultation.

To view the entire article at its original location click on the title of this post.

AdMark China is committed to finding for our clients the best possible talent as quickly as possible. Contact us at info@admarkchina.com or at +86 21 6288 9292.